Adults with type 2 diabetes mellitus (T2DM) have a 2-4 fold increased risk for cardiovascular (CV) morbidity and mortality. This session cuts to the heart of primary and secondary prevention in this population, presenting recent data on antihyperglycemic medications with proven cardiovascular benefit in the context of updated management algorithms. Individualized treatment is critical to the success of these treatment plans. The faculty will help you optimize adherence through shared decision-making tactics that account for CV risk factors, comorbidities, and patient preferences.
- Recognize the central role of primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus (T2DM)
- Appraise recent data on antihyperglycemic medications with proven cardiovascular (CV) benefit
- Consult updated T2DM management algorithms that emphasize CV history when considering antihyperglycemic therapies
- Apply a shared-decision making model to select antihyperglycemic agents based on an individual patient’s CV risk, comorbidities, and preferences
Session supported by Lilly